NCT06405321 Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
| NCT ID | NCT06405321 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Guangxi Medical University |
| Condition | Hepatocellular Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2019-01-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2019-01-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This multicenter retrospective study which included patients with hepatocellular carcinoma (HCC) who received conversion or neoadjuvant therapy to explore the best treatment options and the best benefit group.
Eligibility Criteria
Inclusion Criteria: * Histologically or clinically confirmed diagnosis of HCC. * Patients who received conversion or neoadjuvant therapy as initial treatment, including hepatic artery infusion chemotherapy (HAIC), transcatheter arterial chemoembolization (TACE), tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), or radiotherapy. * Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 or 1. * With Child-Pugh 5\~7 scores. Exclusion Criteria: * Concurrent with other malignancies within 5 years. * Incomplete medical data. * Follow-up time less than 3 months.
Contact & Investigator
Jian-Hong Zhong, Ph.D
PRINCIPAL INVESTIGATOR
Guangxi Medical University Cancer Hospital
Frequently Asked Questions
Who can join the NCT06405321 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06405321 currently recruiting?
Yes, NCT06405321 is actively recruiting participants. Contact the research team at zhongjianhong66@163.com for enrollment information.
Where is the NCT06405321 trial being conducted?
This trial is being conducted at Nanning, China.
Who is sponsoring the NCT06405321 clinical trial?
NCT06405321 is sponsored by Guangxi Medical University. The principal investigator is Jian-Hong Zhong, Ph.D at Guangxi Medical University Cancer Hospital. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.